Sebaceous gland carcinoma: the lump that mimics a chalazion
Sebaceous gland carcinoma is rare, but it is the most commonly missed eyelid cancer. It looks and behaves like a recurrent chalazion. If a chalazion keeps coming back in the same spot on the same eyelid, that is the single most important warning sign there is.
A rare cancer arising from the oil-producing glands of the eyelid
The eyelid contains two types of sebaceous (oil-producing) gland: the meibomian glands, which sit within the tarsal plate and open at the lid margin, and the glands of Zeis, which are associated with the eyelash follicles. Sebaceous gland carcinoma can arise from either. The meibomian glands, being larger and more numerous, are the more common site of origin.
Sebaceous gland carcinoma accounts for roughly 1 to 5% of eyelid malignancies in Western populations, though it is proportionally more common in Asian populations. It has a predilection for the upper eyelid, which reflects the greater density of meibomian glands there. It is more common in women and in older patients, typically those over sixty.
What makes this tumour particularly important to understand is not its frequency, but its behaviour. It is the eyelid cancer most likely to be misdiagnosed, most likely to be treated as something benign for an extended period, and, partly as a consequence, carries the highest mortality rate of the common eyelid malignancies.
Why sebaceous gland carcinoma is so often mistaken for something else
In ophthalmic oncology circles, sebaceous gland carcinoma has long been called a "masquerade tumour." This is not a compliment to the cancer; it is a recognition of its extraordinary ability to impersonate benign conditions.
The most common presentation is a firm, painless lump within the eyelid that recurs after incision and curettage, exactly as a chalazion would. The patient and often the clinician treat it as a recurrent chalazion, drain it again, and watch it come back again. This cycle can continue for many months, sometimes years, before the correct diagnosis is reached. In one series, the average delay from first presentation to correct diagnosis was over twelve months.
In other cases, the tumour spreads along the surface of the conjunctiva and eyelid margin in a pattern that mimics severe, treatment-resistant blepharitis or chronic unilateral conjunctivitis. The conjunctiva may look thickened, greasy, or diffusely abnormal. Patients may be told they have a stubborn form of blepharoconjunctivitis and treated with antibiotics and lid hygiene for months.
The cardinal rule in oculoplastic surgery: any chalazion that recurs after treatment in the same location must be sent for histopathological examination. This applies especially in older patients, those with unilateral thickening of the eyelid, or anyone with associated lash loss. Drainage alone, without biopsy, is not appropriate for a recurrent chalazion.
Warning signs that distinguish this from a simple chalazion
Most chalazia are straightforward: a firm, painless lump that develops over days to weeks after a blocked gland, sits freely within the eyelid, and resolves either on its own or after incision and curettage. The following features should raise concern that a lump on the eyelid is something more serious.
- A chalazion or lump in the same eyelid that has recurred two or more times after treatment
- Diffuse thickening or induration of the eyelid, rather than a discrete, freely mobile lump
- Loss of eyelashes (madarosis) from the affected area
- Yellowish or greasy discolouration of the conjunctiva on the inside of the eyelid
- Unilateral, persistent, treatment-resistant blepharitis in an older patient
- Chronic unilateral conjunctivitis or a diffusely thickened, abnormal conjunctiva
- A lump in the upper eyelid in a patient over sixty, particularly a woman
None of these features confirms a diagnosis of sebaceous gland carcinoma. But each one warrants prompt referral to an oculoplastic surgeon, who can perform a biopsy. A biopsy of the eyelid is a brief, comfortable procedure under local anaesthetic that provides a definitive answer.
Sebaceous gland carcinoma can spread, and does
Unlike BCC, sebaceous gland carcinoma carries a genuine risk of metastasis. Regional lymph node involvement occurs in approximately 20 to 28% of cases, and once lymph node metastasis has occurred, five-year survival is significantly reduced. Distant metastasis, most commonly to the liver, lungs, and brain, occurs in a smaller proportion of cases but is associated with poor prognosis.
The prognosis from sebaceous gland carcinoma is closely tied to the stage at which it is diagnosed. Localised tumours, caught before lymph node spread, are treated surgically with good outcomes. Advanced tumours require systemic treatment and are managed by a multidisciplinary oncology team.
This is why the delay in diagnosis that so commonly characterises this cancer matters so much. Every month that passes with a misdiagnosed sebaceous gland carcinoma is a month in which the tumour has the opportunity to spread. The challenge is not the treatment once the diagnosis is established; the challenge is making the diagnosis in the first place.
Wide excision and careful staging
The primary treatment for sebaceous gland carcinoma is wide surgical excision with frozen section or Mohs micrographic surgery for margin control. Because the tumour can spread in a pagetoid (surface-spreading) pattern along the conjunctiva without forming a visible mass, map biopsies of the conjunctiva are often performed at the time of surgery to determine the true extent of involvement.
Sentinel lymph node biopsy is generally recommended for tumours larger than 10 mm or those with high-risk features, to assess regional lymph node status.
Where the tumour is extensive, exenteration of the orbit (removal of the eye and orbital contents) may be necessary in a small number of cases. This is a major procedure and is only considered when no less radical option will achieve clear margins.
Eyelid reconstruction following excision follows the same principles as for other eyelid cancers, adapted to the extent and location of the defect.
If you have a chalazion that has recurred after treatment, a persistent thickening of an eyelid, or an eyelid problem that is not responding as expected, please seek specialist assessment. Mr Chris Matthews can examine and biopsy eyelid lesions and will refer appropriately for oncological management where needed.
Book a consultation ›Common questions
Why is it called the masquerade tumour?
Because it presents in ways that closely mimic common, benign eyelid conditions: particularly a recurrent chalazion, chronic blepharitis, or unilateral conjunctivitis. This mimicry leads to prolonged misdiagnosis, which is the principal reason it carries a higher mortality than other eyelid cancers of comparable stage.
My chalazion keeps coming back. Should I be worried?
A single recurrence of a chalazion after treatment is not unusual and is not cause for alarm. A chalazion that returns repeatedly in the same location, particularly in an older patient, should always be assessed by an oculoplastic surgeon. The correct approach is to send tissue for histopathological examination, which provides a definitive answer.
Is sebaceous gland carcinoma associated with any systemic conditions?
Muir-Torre syndrome is a rare hereditary condition (a variant of Lynch syndrome) that is associated with sebaceous tumours of the skin, including sebaceous gland carcinoma, alongside internal malignancies such as colorectal and endometrial cancer. If a patient has multiple sebaceous tumours, or a personal or family history of these internal cancers, genetic counselling and screening may be appropriate.
How is a biopsy of the eyelid done?
An eyelid biopsy is performed under local anaesthetic in a clinic or minor procedure room. The area is numbed with a small injection, a sample of tissue is removed, and it is sent to a pathology laboratory for examination. The procedure takes a few minutes and is typically very well tolerated. Results are usually available within one to two weeks.
